Floatz logo

ROPEGINTERFERON ALFA-2B

Alfa-2b

M.D. Anderson Cancer Centerprotein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Alfa-2b cohort.

Asset / SponsorPhaseRating
Azacitidine
M.D. Anderson Cancer Center
Phase 1/2CCC

Same molecule, other indications

ROPEGINTERFERON ALFA-2B is also rated in:

AzacitidineDormant
CC
Indicative ·
47 / 100
View asset →
MDS/AMLDormant
CC
Indicative ·
47 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →